BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27543214)

  • 1. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome.
    Lawrence NF; Hammond MR; Frederick DT; Su Y; Dias-Santagata D; Deng A; Selim MA; Mahalingam M; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2016 Sep; 75(3):595-602. PubMed ID: 27543214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofibromin protein loss in desmoplastic melanoma subtypes: implicating NF1 allelic loss as a distinct genetic driver?
    Kadokura A; Frydenlund N; Leone DA; Yang S; Hoang MP; Deng A; Hernandez-Perez M; Biswas A; Singh R; Yaar R; Mahalingam M
    Hum Pathol; 2016 Jul; 53():82-90. PubMed ID: 26980030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma.
    Straume O; Sviland L; Akslen LA
    Clin Cancer Res; 2000 May; 6(5):1845-53. PubMed ID: 10815907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotrophin receptors and perineural invasion in desmoplastic melanoma.
    Frydenlund N; Leone DA; Mitchell B; Yang S; Deng A; Hoang MP; Mahalingam M
    J Am Acad Dermatol; 2015 May; 72(5):851-8. PubMed ID: 25752716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker.
    Lade-Keller J; Riber-Hansen R; Guldberg P; Schmidt H; Hamilton-Dutoit SJ; Steiniche T
    J Clin Pathol; 2014 Jun; 67(6):520-8. PubMed ID: 24607493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma.
    Barr J; Amato CM; Robinson SE; Kounalakis N; Robinson WA
    Melanoma Res; 2012 Feb; 22(1):92-5. PubMed ID: 22189301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional RET G691S polymorphism in cutaneous malignant melanoma.
    Narita N; Tanemura A; Murali R; Scolyer RA; Huang S; Arigami T; Yanagita S; Chong KK; Thompson JF; Morton DL; Hoon DS
    Oncogene; 2009 Aug; 28(34):3058-68. PubMed ID: 19561646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal.
    Miller DD; Emley A; Yang S; Richards JE; Lee JE; Deng A; Hoang MP; Mahalingam M
    Mod Pathol; 2012 Apr; 25(4):505-15. PubMed ID: 22157936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
    Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
    Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16 expression differentiates between desmoplastic Spitz nevus and desmoplastic melanoma.
    Hilliard NJ; Krahl D; Sellheyer K
    J Cutan Pathol; 2009 Jul; 36(7):753-9. PubMed ID: 19519606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression.
    Kraft S; Fernandez-Figueras MT; Richarz NA; Flaherty KT; Hoang MP
    J Am Acad Dermatol; 2017 Sep; 77(3):534-542. PubMed ID: 28728868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic prediction of the immunohistochemical expression of p16 and p53 in cutaneous melanoma: a comparison of two populations from different geographical regions.
    Sirigu P; Piras F; Minerba L; Murtas D; Maxia C; Colombari R; Corbu A; Perra MT; Ugalde J
    Eur J Histochem; 2006; 50(3):191-8. PubMed ID: 16920642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-frequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma.
    Kostaki M; Manona AD; Stavraka I; Korkolopoulou P; Levidou G; Trigka EA; Christofidou E; Champsas G; Stratigos AJ; Katsambas A; Papadopoulos O; Piperi C; Papavassiliou AG
    Exp Dermatol; 2014 May; 23(5):332-8. PubMed ID: 24673285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PUMA expression is significantly reduced in human cutaneous melanomas.
    Karst AM; Dai DL; Martinka M; Li G
    Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma.
    Burton AL; Gilbert J; Farmer RW; Stromberg AJ; Hagendoorn L; Ross MI; Martin RC; McMasters KM; Scoggins CR; Callender GG
    Am Surg; 2011 Aug; 77(8):1009-13. PubMed ID: 21944515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
    Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
    DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
    Sugianto J; Sarode V; Peng Y
    Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.